Global Trade Alert
Global Trade Alert

United States of America: Agreement with Pfizer on most-favored-nation drug pricing and tariff exemption

Announcement

30 Sep 2025

In September 2025, the United States government announced an agreement with Pfizer to implement most-favored-nation drug pricing for American patients. The agreement secured a three-year reprieve for Pfizer from prospective tariffs on the pharmaceutical industry.

Source

Sign in to access

Number of interventions

3

0 certainly harmful

3 likely harmful

0 liberalising

List of interventions

Implementation date

No implementation date

Revocation date:

No revocation date

Clarification: 02 Apr 2026
Local operations incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Clarification: 02 Apr 2026
Tax or social insurance relief
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more
Clarification: 02 Apr 2026
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and related pharmaceutical ingredients. Under the proclamation, a 0% ta...
Sign in to see more

Threads

See all

Harmful Trade Policy Measures

This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.

Published: 04 Sep 2024

70619

interventions

194

jurisdictions

United States: Drug Pricing Agreements

This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...

Published: 11 Nov 2025

68

interventions

2

jurisdictions